

**Symposium at FSGO 2026 Annual Meeting  
Evolving Evidence and Treatment Strategies in Low-Grade Serous  
Ovarian Cancer (LGSOC)  
June 13, 2026  
Longboat Key, FL**

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** \*(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations**.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the **past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

**All of the relevant financial relationships listed for these individuals have been mitigated.** However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

**NEW TERM** \*An "ineligible company" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

LAST NAME	FIRST NAME	Individual's Role(s) in Activity	Name of Ineligible Company(s)	Nature of Relevant Financial Relationship(s)
<b>Planning Disclosures</b>				
Slomovitz, MD	Brian	<b>Moderator</b>	Novocure; AstraZeneca; Aasi; Regeneron; Immunocore; Merck; Gilead; Eisai; Incyte	Consultant
<b>Speaker Disclosures</b>				
Brown, MD	Jubilee	<b>Speaker</b>	Verastem; AbbVie; Natera; Aadi; Eisai; Tract Bio; Caris Life Sciences; Corcept; PMV Pharmaceuticals; AstraZeneca	Consultant
Engbert	Holley	<b>Staff</b>	Nothing to disclose	
Rush	Heather	<b>Staff</b>	Nothing to disclose	
Shumaker	Kara	<b>Reviewer/Staff</b>	Nothing to disclose	
Small, MPH	Michelle N	<b>Reviewer/Staff</b>	Nothing to disclose	
Alvarez Secord, MD	Angeles	<b>Reviewer/Edu-Chair</b>	AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis; Foundation Medicine; Gilead; Histosonics; Medtronic; Porject Nana; Up to Date; SGO; FWC; GOG Foundation; Amgen; Johnson & Johnson	Research funds to Institution (AbbVie; Aravive; AstraZeneca; Daiichi Sankyo; Ellipses Pharma; Genmab; GSK; Immunogen; Karyopharm; Merck; Mersana; Myriad; Oncoquest/Canaria Bio; Oncoquest; Roche/Genentech; TORL Biotherapeutics; Zentalis) Honorarium (Merck; GSK) Advisory Board with Honoraria (AbbVie; AstraZeneca; Daiichi Sankyo; Foundation Medicine; GSK; Genmab; Gilead; Histosonics; Medtronic; Merck) Medical Advisory Board (Porject Nana)

**FACULTY DISCLOSURE INFORMATION**

				Steering Committee Uncomp. (Oncoquest; Genmab) Royalties (Up to Date) Board of Directors (SGO; FWC; GOG Foundation) Stock-Divested in June 2024 (Amgen; Johnson & Johnson)
Duska, MD	Linda	<b>Edu-Co-Chair/ Reviewer</b>	Merck; Corcept	Honoraria (Merck) Speakers Bureau (Corcept) Research Funding (Merck)
Blank, MD	Stephanie	<b>Reviewer</b>	American Board of Obstetrics and Gynecology; Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.	Leadership (American Board of Obstetrics and Gynecology) Research Funding (Merck; AstraZeneca; GlaxoSmithKline; Pfizer; Seattle Genetics/Astellas; Acrivon; Zentalis; NX Development Corp.)
Gien, MD	Lilian	<b>Reviewer</b>	Glaxo Smith Kline; Merck; Abbvie; AstraZeneca	Speaker Honoraria (Glaxo Smith Kline; Merck) Advisory Board (Abbvie; AstraZeneca)
Mutch, MD	David	<b>Reviewer</b>	Nothing to disclose	
Zweizig, MD	Susan	<b>Reviewer</b>	Nothing to disclose	